Özet:

Hepatitis B and hepatitis C infections are the main causes of deaths associated with chronic liver disease. Treatment in the reduction of long-term cirrhosis and hepatocellular carcinoma is very important. In this study, we aimed at identifying real life data in our patients we were treated with hepatitis B and C. Method and Requirements: 30 chronic hepatitis B (KHB), which began treatment between May 2007 and December 2008 in an educational and research hospital in Izmir in the infectious diseases and clinical microbiology clinic, 21 chronic hepatitis C (KHC) patients were examined retrospectively. In chronic hepatitis B patients, the virological response rate to the 48-week pegileinterferon treatment was 57%. However, 85% of patients developing virological response were given oral antiviral therapy due to biochemical and virological inflammation within a year. 2 of the 14 patients treated with Pegileinterferon developed HBeAg seroconversion, while 11 were transmitted to oral antivirus. The patient was subjected to virological and biochemical suppression. In patients treated with Entecavir and Tenofovir, the virological response rates were observed at 91% and 100% in the 48th week of treatment, respectively. In 21 patients with chronic hepatitis C receiving Pegile interferon and ribavirin, the rate of rapid virological response was 71, the rate of early virological response was 100% and the rate of permanent virological response was 100%. CHRONIC HEPATITIS B: We believe that pegile interferon treatment should be given only to selected groups of patients with low viral load and high ALT levels, due to low therapeutic response with high potential side effects. In patients with KHC, direct-effective antivirals (DAA) are recommended treatments today due to the high durable virological responses and much less side effects; in patients selected especially in developing and retarded countries due to the high cost of DAA drugs, combined with ribavirin pegileinterferon alpha 2a or 2b treatment should be considered as an alternative.

Anahtar Kelimeler: